Loading
Cabergoline is a tablet taken once or twice a week that shrinks prolactin-secreting pituitary tumours and normalises hormone levels in most patients, so surgery is reserved for the few whose tumours resist or who cannot tolerate it.
Cabergoline is an ergoline dopamine agonist developed by Farmitalia Carlo Erba, later Pharmacia and now Pfizer. The FDA approved it in 1996 for hyperprolactinaemic disorders. Its long half-life allows dosing once or twice weekly, and it normalises prolactin in roughly 80 to 90 percent of patients and shrinks macroprolactinomas in most, with less nausea than bromocriptine.
It is the first-line treatment for prolactinoma of any size; transsphenoidal surgery is reserved for resistance, intolerance or cystic tumours compressing the optic chiasm. High doses used in Parkinson's disease were linked to cardiac valve fibrosis, so echocardiographic monitoring is advised on long-term higher doses. The pituitary tumours page names it as the standard treatment for prolactinomas.
A potent, long-acting dopamine D2 agonist that suppresses prolactin release from pituitary lactotrophs and shrinks prolactinomas, taken only once or twice a week. Connects to Dopamine D2 receptor.
1.Cabergoline slips into a pocket on Dopamine D2 receptor.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
| Region | Year | Indication |
|---|---|---|
| US | 1996 | Hyperprolactinaemic disorders, idiopathic or due to pituitary adenomas |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Cabergoline" OR ABSTRACT:"Cabergoline" OR TITLE:"Dostinex" OR ABSTRACT:"Dostinex" OR TITLE:"Cabaser" OR ABSTRACT:"Cabaser") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cabergoline, not a curated reading list.
Shares Somatotroph pituitary neuroendocrine tumour (acromegaly), Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Pfizer (incl. Seagen) and the tag subtype-drugs-wave.
Shares Somatotroph pituitary neuroendocrine tumour (acromegaly), Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour), Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag subtype-drugs-wave.
Shares Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour), Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag subtype-drugs-wave.
Shares Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour) and the tag subtype-drugs-wave.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag subtype-drugs-wave.
Shares Pfizer (incl. Seagen) and the tag subtype-drugs-wave.
Shares Somatotroph pituitary neuroendocrine tumour (acromegaly), Lactotroph pituitary neuroendocrine tumour (prolactinoma), Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour), Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma.
Shares Somatotroph pituitary neuroendocrine tumour (acromegaly), Lactotroph pituitary neuroendocrine tumour (prolactinoma), Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma.